Author: Liu Haiying Date: 2018-07-10 A recent study published in The Lancet shows that an experimental HIV-1 vaccine regimen is well tolerated and produces stronger in healthy adults and rhesus monkeys. Immune response. In addition, the vaccine prevents rhesus monkeys from infecting human monkey chimeric immunodeficiency virus (SHIV). Currently, researchers have begun Phase II clinical efficacy trials to determine if the vaccine can prevent HIV infection in humans. The research, led by Dan Baruch, a professor of medicine at Harvard Medical School in Boston, USA, was funded by the US Department of Defense and the National Institutes of Health. The new vaccine is based on the chimeric adenovirus serotype 26 (Ad26) and is a "mosaic" vaccine that is inoculated with different HIV viruses and combined to elicit an immune response against multiple HIV strains. A clinical 1/2a trial involving nearly 400 healthy adults and another parallel study showed that the Ad26/Ad26+gp140 enhanced HIV vaccine not only induces a strong immune response in humans and rhesus monkeys, but also in the Ganges The monkey experiment also provided 67% antiviral protection. Based on the results of the clinical 1/2a trial, the researchers initiated Phase 2b clinical trials in Southern Africa to determine the safety and efficacy of this HIV vaccine candidate in 2,600 women at risk for HIV. The researchers point out that clinical trial results suggest that mosaic HIV vaccines may have the potential to prevent various HIV strains worldwide, and this research is a milestone in HIV-1 vaccine research. But Baruch stressed that these research findings should be interpreted with caution. Because the challenges of HIV vaccine development are unprecedented, the ability to induce an HIV-specific immune response does not necessarily indicate that the vaccine protects humans from HIV infection. The results of the Phase 2b efficacy trial will show whether the vaccine protects humans from HIV infection and they are looking forward to it. Prior to Ad26, only four HIV vaccine programs were tested in humans, and only one program provided evidence of protection in efficacy trials, which reduced human infection rates by 31%, but this effect was considered too low. Therefore, the vaccine cannot be widely used. Source: Technology Daily Elisa Microplate Reader,Laptop Diagnostic Machine,Elisa Microplate Reade,Elisa Immunoassay Machine Guangdong Widinlsa International Co.Ltd , https://www.gdwidinlsa.com